

CLAIMS

1. (Original) A purified polypeptide shown in SEQ ID NO: 2, or a fragment or variant thereof exhibiting at least about 50% sequence homology to the naturally occurring polypeptide, wherein said fragment or variant inhibits platelet function.
2. (Original) A polypeptide according to claim 1 which interferes with the binding of at least one cell surface integrin with its respective ligand.
3. (Currently Amended) A polypeptide according to claim 2 ~~is~~ wherein the integrin is GPIIb/IIIa ($\alpha_{IIb}\beta_3$) and the ligand is fibrinogen.
- A1 4. (Original) A polypeptide according to claim 2 wherein the integrin is GPIa/IIa ($\alpha_2\beta_1$) and the ligand is collagen.
5. (Original) A polypeptide according to claim 2 which interferes with the binding of more than one integrin.
6. (Original) A polypeptide according to claim 1 which inhibits both platelet aggregation and platelet adhesion.
7. (Original) A polypeptide according to claim 1 shown in SEQ ID NO: 2.
8. (Original) A pharmaceutical composition comprising the polypeptide of claim 1.
9. (Original) A method for treating a patient comprising administering a composition comprising an effective amount of the polypeptide according to claim 1 to the patient to inhibit platelet function.

10. (Original) A composition for inducing the immune response of a mammal comprising the polypeptide of claim 1.

11. (Original) A composition for inducing the immune response of a mammal susceptible to hookworm infection comprising the polypeptide of claim 1.

12. (Currently Amended) ~~A~~ A purified polypeptide isolated or cloned from hookworms selected from the group consisting of *Ancylostoma duodenale*, *Ancylostoma ceylanicum*, *Necator americanus*, and *Ancylostoma caninum*, which inhibits platelet function.

A/

13. (Original) A polypeptide according to claim 12 isolated from *Ancylostoma caninum*.

14. (Original) A polypeptide according to claim 12 which inhibits the binding of fibrinogen to cell surface integrin GPIIb/IIIa ($\alpha_{IIb}\beta_3$).

15. (Original) A polypeptide according to claim 12 which inhibits the binding of collagen to cell surface integrin GPIa/IIa ($\alpha_2\beta_1$).

16. (Original) A polypeptide according to claim 12 which inhibits platelet aggregation in response to an agonist selected from the group consisting of epinephrine, thrombin, and ADP.

17. (Original) A pharmaceutical composition comprising the polypeptide of claim 12.

Serial No.: 09/937,555
Filed: February 20, 2002

Art Unit: 1653
Examiner: C.M. Kam

18. (Original) A method for treating a patient comprising administering a composition comprising an effective amount of the polypeptide according to claim 12 to the patient to inhibit platelet function.

A1

19. (Original) A composition for inducing the immune response of a mammal susceptible to hookworm infection comprising the polypeptide of claim 12.

20. (Canceled)
